Anti-hyperalgesia properties of buprenorphine.
Russo
Marc A
MA
D000286:Administration, Sublingual; D000328:Adult; D000465:Algorithms; D000701:Analgesics, Opioid / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use*; D001682:Biological Availability; D002047:Buprenorphine / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006930:Hyperalgesia / Q000139:chemically induced / Q000175:diagnosis / Q000517:prevention & control*; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D015233:Models, Statistical; D010146:Pain / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D010147:Pain Measurement / Q000706:statistics & numerical data; D010919:Placebos; D017450:Receptors, Opioid, mu / Q000819:agonists / Q000187:drug effects; D004561:Transcutaneous Electric Nerve Stimulation / Q000379:methods; D016896:Treatment Outcome
D000701:Analgesics, Opioid; D010919:Placebos; D017450:Receptors, Opioid, mu; D002047:Buprenorphine